In the latest international pandemic developments, a closely watched large phase 3 trial of four treatments for COVID-19—including remdesivir—found little or no benefit for survival, and as new spikes accelerated in the United States and Europe, the global total topped 39 million cases.The findings about remdesivir leave doctors uncertain on how to proceed, given that some countries, including the United States, have already granted the drug emergency use authorization.
They also leave health authorities, including the World Health Organization (WHO), scrambling to review the latest data to update their treatment guidelines.